News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017

IUCT Oncopole Installs First Radixact Radiotherapy System in France

French cancer institute building re-irradiation and adaptive radiotherapy program using the latest technology developed by Accuray

IUCT Oncopole Installs First Radixact Radiotherapy System in France

June 20, 2017 — Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France, is providing advanced radiation treatments to cancer patients using the smart Radixact Treatment Delivery System, the first to be installed in France. The IUCT Oncopole began treating patients in January with this new system, designed to deliver image-guided intensity-modulated radiation therapy (IG-IMRT), an extremely precise form of radiation therapy.

"The acquisition of innovative equipment, including the Radixact System, is part of our strategy to offer best-in-class cancer care to all patients in the region," said Prof. Elizabeth Moyal, head of the Radiotherapy Department at the IUCT Oncopole. "What makes the Radixact technology so special is that its sophisticated tools enable us to use progressive clinical approaches such as re-irradiation and adaptive therapy to ensure patients receive the optimal treatment for them, at every stage of their cancer journey." 

The Radixact System is the next-generation TomoTherapy platform. Fully integrated with the Accuray Precision Treatment Planning System and the iDMS Data Management System, the system enables clinicians to achieve the best possible treatment outcomes.

The system has been designed to facilitate faster image acquisition and treatment delivery, allowing the clinical team to provide precise radiation treatments to more patients, every day. The system features a more powerful linear accelerator, low-dose fan beam megavoltage computed tomography (MVCT) imaging and unique helical delivery technology, so clinicians can apply highly conformal and homogenous dose distributions to any target volume, while minimizing dose to surrounding normal healthy tissue, during each treatment fraction. Smart, automated workflows and midcourse decision-making tools enable clinicians to adapt delivery to changes in tumor size, shape and location within the patient.

The Radixact System is capable of treating all standard radiation therapy indications such as brain, breast, head and neck, prostate, and rectal and spine cancers, in addition to complex treatments such as total marrow irradiation. It is so precise that, should the cancer re-occur, the patient can be re-treated on the Radixact System, according to Accuray. As explained by Moyal, "We have successfully administered treatment for several types of cancers so far including breast cancer, head and neck cancers, and pediatric tumors which we previously treated on a routine basis using the TomoTherapy System. Moving forward we plan to use the Radixact System to provide treatment for abdominal, hematologic and pelvic tumors, indications which will also benefit from the system's advanced adaptive therapy capabilities."

For more information: www.accuray.com

Related Content

Hippocampal Sparing Prevents Whole-Brain Radiotherapy Cognitive Side Effects
News | Radiation Therapy | October 23, 2018
Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus,...
Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.
Feature | Artificial Intelligence | October 22, 2018 | By Greg Freiherr
Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them be
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...

Image courtesy of Vital Images

News | ASTRO | October 22, 2018
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one
Fewer, larger individual doses of radiation lead to similar adverse effects to normal tissue after 10 years as with conventional radiation therapy for early breast cancer
News | ASTRO | October 22, 2018
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer,
Patients whose cancer has not spread far past the lungs may benefit from targeting tumor sites with radiation or surgery after initial treatment, according to ASTRO study
News | ASTRO | October 21, 2018
Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to
DCIS, ductal carcinoma in situ, radiation therapy, survival benefit, Brigham and Women's Hospital study

Image courtesy of Barco

News | ASTRO | October 21, 2018
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservatio
The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

Feature | ASTRO | October 20, 2018 | By Greg Freiherr
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S.
The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t